Get the content you want anytime you want.
REGISTER NOW | SIGN IN
<< View All Contributors
Saskia v. Popescu, MPH, MA, CIC, is a hospital epidemiologist and infection preventionist with Phoenix Children's Hospital. During her work as an infection preventionist she performed surveillance for infectious diseases, preparedness, and Ebola-response practices. She is currently a PhD candidate in Biodefense at George Mason University where her research focuses on the role of infection prevention in facilitating global health security efforts. She is certified in Infection Control.

Going Against the Norm: Testing A New Skin Disinfectant

AUG 27, 2018 | SASKIA V. POPESCU
Decolonizing a patient’s skin is critical for reducing microbial burden during hospitalization, especially before surgery to reduce the risk of surgical site infections, as well as other health care-associated infections (HAIs). Topical antiseptics are commonly used to clean and decolonize patients who may be going into surgery or those who are unable to clean themselves and who are at risk for infection (ie, patients in intensive care units). The use of these antiseptics come with added caveats, though, and so, there is a continued push for finding new methods for decolonizing patients’ skin.

The gold standard topical antiseptic is chlorhexidine gluconate because it can quickly and effectively rid the skin of microbes; however, there is also a risk for skin irritation and allergies when using the antiseptic, which can result in skin breakdown and pain for the patient. Moreover, chlorhexidine gluconate should not be used on patients with compromised skin. With concern for microbial resistance continuing to grow, scientists are searching for new agents that can be used for disinfection and decolonization on all groups of patients.

As such, the authors of a new research study tested a multi-ingredient surfactant colloidal silver technology to see if it was noninferior to a 4% chlorhexidine gluconate antiseptic.

The team of investigators recruited 81 participants in Bozeman, Montana, who were in good health and who, for 14 days before the test portion of the study, avoided medicated soaps, lotions, deodorants, shampoos, and skin contact with solvents, detergents, etc. Seventy-two hours before the experiment, the investigators screened a skin sample via a sterile cylinder in which the 3.46 cm inside the cylinder was the test area. On each participant, they marked 4 areas of the inguinal region, of which 3 were then sampled (1 as a baseline, 1 at 10 minutes, and 1 at 6 hours). These sites were sampled for microbial loads after 6 hours were covered with sterile gauze and bandages and then sampled. The investigators then plated the samples and microbial colonies were manually counted and data was then assessed.

A total of 40 participants received colloidal silver and 41 received 4% chlorhexidine gluconate as treatments.

For the 10-minute group, the investigators found the mean recovery of microbial flora to be 3.83 for colloidal silver and 3.64 for 4% chlorhexidine gluconate, while the 6-hour group had a recovery average of 3.49 for colloidal silver and 3.34 for 4% chlorhexidine gluconate. The average treatment efficacy was .18-.21, meaning that the colloidal silver was noninferior to the 4% chlorhexidine gluconate. The investigators note that “the 95% confidence interval of the test product to the control product with a margin of 0.65 was established as the upper limit of noninferiority.” 

Ultimately, the treatments were of similar efficacy and although the sample size was small, the results should prove encouraging for future efforts to find nonchlorhexidine gluconate antiseptics for skin decolonization.

Furthermore, the research is timely given the latest US Food and Drug Administration guidance that warned of a greater chance for safety concerns related to chlorhexidine gluconate-containing products. Since chlorhexidine gluconate is widely used, alternatives should be investigated for future application and hopefully, they will prove less abrasive to the skin, but still efficacious against hardy microbes. 
 
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.
FEATURED
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.
More from Saskia v. Popescu
Insight into healthcare exposures gives us a new reason to invest in surveillance tools
PUBLISHED: Tue May 21 2019
The latest on this ever-changing and complex outbreak.
PUBLISHED: Mon May 20 2019
A new study gives hope in the fight against multidrug-resistant bacteria.
PUBLISHED: Thu May 16 2019
One company's bankruptcy sheds light on a deeply worrisome reality.
PUBLISHED: Mon May 13 2019